Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Drops By 14.3%

AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) was the target of a large drop in short interest in February. As of February 15th, there was short interest totalling 1,140,000 shares, a drop of 14.3% from the January 31st total of 1,330,000 shares. Based on an average daily trading volume, of 442,700 shares, the days-to-cover ratio is presently 2.6 days. Approximately 3.0% of the shares of the stock are sold short.

Insider Buying and Selling at AngioDynamics

In other AngioDynamics news, SVP Dave Helsel sold 4,633 shares of the firm’s stock in a transaction that occurred on Tuesday, January 31st. The stock was sold at an average price of $12.95, for a total transaction of $59,997.35. Following the completion of the transaction, the senior vice president now owns 19,189 shares in the company, valued at approximately $248,497.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its holdings in AngioDynamics by 1.9% during the 3rd quarter. BlackRock Inc. now owns 6,411,415 shares of the medical instruments supplier’s stock worth $131,177,000 after purchasing an additional 117,895 shares during the period. Victory Capital Management Inc. increased its holdings in AngioDynamics by 47.3% during the 4th quarter. Victory Capital Management Inc. now owns 4,261,474 shares of the medical instruments supplier’s stock worth $58,680,000 after purchasing an additional 1,369,109 shares during the period. Dimensional Fund Advisors LP increased its holdings in AngioDynamics by 1.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,750,872 shares of the medical instruments supplier’s stock worth $59,255,000 after purchasing an additional 46,173 shares during the period. Vanguard Group Inc. increased its holdings in AngioDynamics by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,589,323 shares of the medical instruments supplier’s stock worth $52,977,000 after purchasing an additional 38,898 shares during the period. Finally, Millennium Management LLC increased its holdings in AngioDynamics by 121.5% during the 4th quarter. Millennium Management LLC now owns 1,953,005 shares of the medical instruments supplier’s stock worth $26,893,000 after purchasing an additional 1,071,419 shares during the period. 94.94% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Raymond James lowered their price objective on AngioDynamics from $25.00 to $22.00 and set a “strong-buy” rating for the company in a research note on Friday, January 6th.

AngioDynamics Price Performance

Shares of ANGO stock opened at $12.51 on Friday. AngioDynamics has a 52-week low of $11.71 and a 52-week high of $24.87. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.30 and a current ratio of 2.16. The firm has a market capitalization of $489.52 million, a P/E ratio of -15.07 and a beta of 0.62. The stock has a 50 day moving average price of $13.30 and a 200 day moving average price of $15.52.

AngioDynamics (NASDAQ:ANGO – Get Rating) last issued its quarterly earnings results on Thursday, January 5th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. AngioDynamics had a negative return on equity of 0.14% and a negative net margin of 9.98%. The firm had revenue of $85.43 million during the quarter, compared to analyst estimates of $84.05 million. As a group, sell-side analysts predict that AngioDynamics will post 0.01 earnings per share for the current year.

About AngioDynamics

(Get Rating)

AngioDynamics, Inc is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products.